Jasper Therapeutics reports 68.94% of warrants tendered in $0.324-per-warrant buyback offer

Jasper Therapeutics (Nasdaq: JSPR) announced on November 9, 2026 the results of its cash tender offer for warrants issued in its September 2025 underwritten public offering, which expired November 7, 2026. Holders tendered 8,510,658 warrants, about 68.94% of those outstanding, and the company expects to pay roughly $2.76 million at $0.324 per warrant. The offer was made under a Schedule TO filed with the SEC on October 7, 2026.

09 Nov 2026 · Jasper Therapeutics, Inc. JSPR · Company news

Company's press release (SEC filing): Jasper Therapeutics, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More FinancingAll →

Financing

Jasper Therapeutics reports 68.94% of warrants tendered in $0.324-per-warrant buyback offer

IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M

Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597

Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants

Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities

Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds

Lichen International prices $3.5M registered direct offering of units with warrants on Nasdaq